1,435 results on '"Seaman, Michael"'
Search Results
2. Human CD4-binding site antibody elicited by polyvalent DNA prime-protein boost vaccine neutralizes cross-clade tier-2-HIV strains
3. Autologous neutralizing antibodies increase with early antiretroviral therapy and shape HIV rebound after treatment interruption
4. Dynamics and durability of HIV-1 neutralization are determined by viral replication
5. Structural and functional characteristics of the SARS-CoV-2 Omicron subvariant BA.2 spike protein
6. Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans
7. Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
8. Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility
9. Mpox infection protects against re-challenge in rhesus macaques
10. Anti-V1/V3-glycan broadly HIV-1 neutralizing antibodies in a post-treatment controller
11. On the Distribution of Discriminants over a Finite Field
12. Correction for Kibler et al., “Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC”
13. Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage
14. Prolonged viral suppression with anti-HIV-1 antibody therapy
15. Combination anti-HIV antibodies provide sustained virological suppression
16. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
17. A randomized controlled trial on the interconnected systems framework for school mental health and PBIS: Focus on proximal variables and school discipline
18. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques
19. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope
20. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC.
21. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
22. Broadly neutralizing antibody-mediated protection against simian-HIV infection among macaques with vaginal sexually transmitted infections
23. Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life
24. Identification of IOMA-class neutralizing antibodies targeting the CD4-binding site on the HIV-1 envelope glycoprotein
25. Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters
26. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
27. Relationship between latent and rebound viruses in a clinical trial of anti–HIV-1 antibody 3BNC117
28. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques
29. Induction of durable remission by dual immunotherapy in SHIV-infected ART-suppressed macaques
30. A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope
31. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
32. Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent D-peptide HIV entry inhibitor
33. A minor population of macrophage-tropic HIV-1 variants is identified in recrudescing viremia following analytic treatment interruption
34. Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.
35. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller
36. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA
37. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
38. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial
39. Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)
40. Framework Mutations of the 10-1074 bnAb Increase Conformational Stability, Manufacturability, and Stability While Preserving Full Neutralization Activity
41. Vaccine targeting SIVmac251 protease cleavage sites protects macaques against vaginal infection
42. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens
43. Human CD4-Binding Site Antibody Elicited by Polyvalent DNA Prime-Protein Boost Vaccine Neutralizes Cross-Clade Tier-2-HIV Strains
44. Deep generative models predict SARS-CoV-2 Spike infectivity and foreshadow neutralizing antibody escape
45. A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo.
46. Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope
47. 802: KETOGENIC DIET IN THE TREATMENT OF FIRES-ASSOCIATED SRSE: FAD OR FACT?
48. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes
49. Induction of HIV-1–Specific Mucosal Immune Responses Following Intramuscular Recombinant Adenovirus Serotype 26 HIV-1 Vaccination of Humans
50. Intra-Spike Crosslinking Overcomes Antibody Evasion by HIV-1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.